Using an external tracking device can lead to super-resolution that can potentially improve neurological disorder detection.
A new PET imaging technique uses the head motions that usually cause problems during brain imaging to produce scans that have the potential to detect neurological disorders, including Alzheimer’s disease, at their earliest stages.
In a poster presented during the Society of Nuclear Medicine and Molecular Imaging 2021 Annual Meeting, investigators from the Gordon Center for Medical Imaging in Boston showed how combining PET with an external motion tracking device can produce highly detailed brain images. It’s a process dubbed super-resolution, they said, and it could lead to faster diagnosis and treatment.
For more SNMMI 2021 coverage, click here.
Typically, unwanted patient movements during scanning degrades image quality. But, the team, led by Yanis Chemli, MSc, Ph.D. candidate at the Gordon Center, determined focusing on and measuring those movements can actually improve resolution.
“This work shows that one can obtain PET images with a resolution that outperforms the scanner’s resolution by making use, counterintuitively perhaps, of usually undesired patient motion,” Chemli said. “Our technique not only compensates for the negative effects of head motion on PET image quality, but it also leverages the increased sampling information associated with imaging of moving targets to enhance the effective PET resolution.”
Result of the Hoffman brain phantom study. Top row: same PET slice reconstructed with A) 2mm static OSEM, B) 1mm static OSEM, C) proposed SR method and D) corresponding CT slice (note that the CT image can be treated as a high-resolution reference). Middle row: zoom on region of interest for corresponding images. Bottom row: Line profiles for corresponding data.
Credit: Image created by Y Chemli, et al., Gordon Center for Medical Imaging: Department of Radiology Massachusetts General Hospital, Harvard Medical School, Boston, MA.
For the study, the team performed moving phantom and non-human primate experiments on a PET scanner with an external motion tracking device that continuously captured extremely precise measurements of head movements. They also completed static reference PET acquisitions without induced movements.
The researchers combined data from the PET scanner and the external tracker, and they recovered PET images that had noticeably higher resolution than what the static reference scans were able to achieve.
Although this super-resolution technique has only been tested in pre-clinical environments, work is underway to extend it to human patients. Ultimately, Chemli said, the technique could have a significant impact on brain disorders, specifically Alzheimer’s.
“Alzheimer’s disease is characterized by the presence of tangles composed of tau protein. These tangles start accumulating very early on in Alzheimer’s disease – sometimes decades before symptoms – in very small regions of the brain,” he said. “The better we can image these small structures in the brain, the earlier we may be able to diagnose and, perhaps in the future, treat Alzheimer’s disease.”
For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.